Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 1/2 3Phase 3 2Phase 2/3 2Phase 1 1

Status

Recruiting 5Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myasthenia Gravis 1Graft vs Host Disease 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 6Oxaliplatin 5Cyclophosphamide 4Azacitidine 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × blinatumomab × Clear all
NCT07297914 2025-12-22

FORUM2

Bambino Gesù Hospital and Research Institute

Phase 2/3 Not yet recruiting
1,000 enrolled
LymphoidOther hematologic neoplasm

Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡